Comparison of the efficacy and safety of sedation between dexmedetomidine and propofol during endoscopic retrograde cholangiopancreatography: prospective, randomized, single-blinded trial

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200061468

Enrollment

Unknown

Registered

2022-06-25

Start date

2022-06-13

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreaticobiliary pathologies

Interventions

DEX group :dexmedetomidine

PRO group:propofol

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged between 18 to 80 years; 2. American Society of Anesthesiologists Physical Status (ASA) I to III.

Exclusion criteria

Exclusion criteria: 1. Previous allergy to midazolam/Sufentanil/dexmedetomidine/propofol; 2. Pregnant patients; 3. The patient refused to participate.

Design outcomes

Primary

Measure	Time frame
sedation-related adverse events;	—

Secondary

Measure	Time frame
Ramsay sedation score;bispectral index of EEG;oxygen saturation;mean arterial pressure;respiratory rate;heart rate;	—

Countries

China

Contacts

Public ContactWang Junlu

wangjunlu973@163.com+86 13806689854

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026